Topics

Regenacy Pharma Earns $30 Million Series A to Advance Diabetic Neuropathy Drug

20:00 EDT 25 Mar 2020 | BioSpace

“We are fortunate to have the strong support of investors aligned with our mission to provide lasting relief of all symptoms of diabetic peripheral neuropathy,” said Simon Jones, Regenacy’s president and chief executive officer.

Original Article: Regenacy Pharma Earns $30 Million Series A to Advance Diabetic Neuropathy Drug

NEXT ARTICLE

More From BioPortfolio on "Regenacy Pharma Earns $30 Million Series A to Advance Diabetic Neuropathy Drug"

Quick Search

Relevant Topic

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...